Increased Angiotensin II Type 1 Receptor Expression in Temporal Arteries from Patients with Giant Cell Arteritis

Ophthalmology

Volumn 116, Issue 5, 2009, Pages 990-996

  Dimitrijevic, Ivan ^a   Malmsjö, Malin ^a   Andersson, Christina ^a   Rissler, Pehr ^a   Edvinsson, Lars ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; EOSIN; FORMALDEHYDE; HEMATOXYLIN; PARAFFIN; POLYCLONAL ANTIBODY;

AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROL GROUP; CONTROLLED STUDY; ENDOTHELIUM CELL; EXPERIMENTAL STUDY; FEMALE; GIANT CELL; GIANT CELL ARTERITIS; HISTIOCYTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SMOOTH MUSCLE FIBER; TEMPORAL ARTERY; VASCULAR SMOOTH MUSCLE;

AGED; AGED, 80 AND OVER; ENDOTHELIUM, VASCULAR; FEMALE; GIANT CELL ARTERITIS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RETROSPECTIVE STUDIES; TEMPORAL ARTERIES;

EID: 65349092825     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2008.12.021     Document Type: Article

References (29)

1. Hunder G.G. Clinical features of GCA/PMR. Clin Exp Rheumatol 18 suppl (2000) S6-S8
2. Weyand C.M., and Bartley G.B. Giant cell arteritis: new concepts in pathogenesis and implications for management. Am J Ophthalmol 123 (1997) 392-395
3. Poller D.N., van Wyk Q., and Jeffrey M.J. The importance of skip lesions in temporal arteritis. J Clin Pathol 53 (2000) 137-139
4. Rauzy O., Fort M., Nourhashemi F., et al. Relation between HLA DRB1 alleles and corticosteroid resistance in giant cell arteritis. Ann Rheum Dis 57 (1998) 380-382
5. Carroll S.C., Gaskin B.J., and Danesh-Meyer H.V. Giant cell arteritis. Clin Exp Ophthalmol 34 (2006) 159-173
6. Proven A., Gabriel S.E., Orces C., et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 49 (2003) 703-708
7. Nuenninghoff D.M., and Matteson E.L. The role of disease-modifying antirheumatic drugs in the treatment of giant cell arteritis. Clin Exp Rheumatol 21 suppl (2003) S29-S34
8. Ruiz-Ortega M., Lorenzo O., Ruperez M., et al. Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ Res 86 (2000) 1266-1272
9. Mezzano S., Droguett A., Burgos M.E., et al. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int Suppl (2003) S64-S70 (86)
10. Sadoshima J. Cytokine actions of angiotensin II. Circ Res 86 (2000) 1187-1189
11. Halkin A., and Keren G. Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. Am J Med 112 (2002) 126-134
12. Cipollone F., Fazia M., Iezzi A., et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 109 (2004) 1482-1488
13. Hunder G.G., Bloch D.A., Michel B.A., et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33 (1990) 1122-1128
14. Salvarani C., Cantini F., Boiardi L., and Hunder G.G. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347 (2002) 261-271
15. Tsuzuki S., Ichiki T., Nakakubo H., et al. Molecular cloning and expression of the gene encoding human angiotensin II type 2 receptor. Biochem Biophys Res Commun 200 (1994) 1449-1454
16. Furuta H., Guo D.F., and Inagami T. Molecular cloning and sequencing of the gene encoding human angiotensin II type 1 receptor. Biochem Biophys Res Commun 183 (1992) 8-13
17. Kim S., and Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52 (2000) 11-34
18. Weber K.T. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 15 (2000) 264-272
19. Levy B.I., Benessiano J., Henrion D., et al. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest 98 (1996) 418-425
20. Brilla C.G., Janicki J.S., and Weber K.T. Impaired diastolic function and coronary reserve in genetic hypertension: role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 69 (1991) 107-115
21. Baker K.M., and Aceto J.F. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol 259 (1990) H610-H618
22. Zhuo J., Moeller I., Jenkins T., et al. Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptors. J Hypertens 16 (1998) 2027-2037
23. Diet F., Pratt R.E., Berry G.J., et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 94 (1996) 2756-2767
24. Schieffer B., Schieffer E., Hilfiker-Kleiner D., et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 101 (2000) 1372-1378
25. Shimada K., and Yazaki Y. Binding sites for angiotensin II in human mononuclear leucocytes. J Biochem 84 (1978) 1013-1015
26. Suzuki H., Shibata H., Murakami M., et al. Modulation of angiotensin II type 1 receptor mRNA expression in human blood cells: comparison of platelets and mononuclear leucocytes. Endocr J 42 (1995) 15-22
27. Rasini E., Cosentino M., Marino F., et al. Angiotensin II type 1 receptor expression on human leukocyte subsets: a flow cytometric and RT-PCR study. Regul Pept 134 (2006) 69-74
28. Hahn A.W., Jonas U., Buhler F.R., and Resink T.J. Activation of human peripheral monocytes by angiotensin II. FEBS Lett 347 (1994) 178-180
29. Ruiz-Ortega M., Ruperez M., Lorenzo O., et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl 82 (2002) S12-S22